Rheumatology wRVU Compensation in 2026: Benchmarks, Infusion Revenue, Panel Management, and What to Ask Before You Sign

Rheumatology compensation has a structure most physicians outside the specialty do not understand. The wRVU portion of compensation is modest — median $52/wRVU at 4,600 wRVUs annually. The real revenue engine for most rheumatology practices is the infusion suite. Biologic drug infusions (Remicade, Orencia, Rituxan, and others) generate substantial buy-and-bill revenue — sometimes $200,000-$600,000 annually per active rheumatologist — and the contract terms governing how that revenue is distributed determine the actual financial structure of the job.

If you are a rheumatologist evaluating a contract — finishing fellowship, switching practices, or considering a private group versus hospital employment — here is what the 2026 market actually looks like and where the financial issues hide.

What the 2026 rheumatology benchmarks actually are

Based on MGMA 2025 data, the median rheumatologist produces approximately 4,600 wRVUs annually at $52 per wRVU. Total compensation at the median runs $260,000-$295,000 in pure clinical roles. Rheumatologists in practices with significant infusion revenue often substantially exceed this — total compensation in the $400,000-$550,000 range is achievable with the right contract structure.

The 75th percentile rheumatologist produces around 5,900 wRVUs annually. The 90th percentile is 7,300.

Rheumatology is largely cognitive and not significantly affected by the 2026 CMS efficiency adjustment.

The three rheumatology contract traps

Infusion revenue retained entirely by the practice. This is the biggest financial trap in rheumatology contracts. Biologic infusions generate substantial drug margin revenue — the practice purchases biologics from the wholesaler and bills the payer for administration plus drug, capturing the spread. For an active rheumatologist with a moderate infusion patient panel, this margin can total $200,000-$600,000 annually.

Many contracts retain this revenue entirely with the practice, paying the rheumatologist a base salary or wRVU bonus that does not reflect the infusion margin generated by their patients. Fair contract language addresses this — either the infusion margin flows to a bonus pool that includes the rheumatologist whose patients are infused, or the per-wRVU rate is elevated to capture a share of the practice revenue.

Panel size and access requirements buried in administrative language. Rheumatology contracts often include language requiring you to maintain a defined panel size or to keep new patient access within a defined window. These targets rarely match the realities of rheumatology care, where complex autoimmune patients require longer visits, frequent lab review, and significant communication with primary care and other specialists.

Negotiate for panel sizes and access targets that reflect the clinical complexity of rheumatologic disease.

Volume-based bonuses tied to procedure metrics that conflict with clinical judgment. Some rheumatology contracts include incentive language tied to joint injection volumes or other procedural metrics. This creates a financial incentive that can conflict with appropriate clinical decision-making. Joint injections have specific indications; performing them for revenue rather than clinical need is bad medicine.

What fair rheumatology contract language looks like

On the wRVU structure: a threshold at or below the 50th percentile (around 4,600 wRVUs) with a rate at or above $52/wRVU.

On infusion revenue: explicit language ensuring infusion margin flows back to the rheumatologist either through a transparent revenue share or through an elevated per-wRVU rate. This is the single most important financial term in most rheumatology contracts.

On panel size: explicit upper bound on panel size with renegotiation if patient demand pushes the panel higher.

On volume incentives: avoid contracts with procedural volume bonuses that could conflict with clinical judgment.

What to ask before you sign

Four specific questions worth getting answered in writing before you commit to a rheumatology contract:

1. What happens with infusion margin revenue from biologic drugs administered to my patients — does it flow back to me through a revenue share, an elevated per-wRVU rate, or is it retained entirely by the practice?
2. What is the maximum panel size I will be required to maintain, and what are the new patient access requirements?
3. Are there volume-based bonuses tied to procedure metrics (joint injections), and if so, how are the thresholds set?
4. What was the average total compensation paid to rheumatologists at the practice over the past 3 years, including infusion revenue distributions?

These are reasonable questions. Vague answers on infusion revenue, panel size, or compensation history tell you exactly how the math will work in practice.

Want to know how your specific rheumatology contract compares to these benchmarks? FairRVU runs the full analysis in 60 seconds — wRVU threshold percentile, infusion revenue distribution analysis, panel size review, and total compensation comparison. Your contract is permanently deleted after processing.